医学
前列腺癌
养生
队列
中性粒细胞减少症
不利影响
内科学
毒性
肿瘤科
放射性核素治疗
临床研究阶段
贫血
临床终点
发热性中性粒细胞减少症
加药
癌症
队列研究
阿尔法(金融)
恩扎鲁胺
最大耐受剂量
性能状态
前瞻性队列研究
胃肠病学
前列腺
药代动力学
作者
Scott T. Tagawa,Charlene Thomas,Abdul Arham,Aaron Holmes,Valentina Marulanda Corzo,Tobechukwu Okobi,Shankar Vallabhajosula,Vasilios Avlonitis,Sandra Huicochea Castellanos,Jones Trevor Nauseef,Elisabeth O’Dwyer,Maham Fatima,Peter Gregos,Sarah Yuan,Cora Nanette Sternberg,Ana M. Molina,David M. Nanus,Neil Harrison Bander,Joseph R. Osborne
标识
DOI:10.1158/1078-0432.ccr-26-0689
摘要
PURPOSE: To test the safety of two regimens at differing levels of radioactivity of prostate-specific membrane antigen (PSMA)-targeted α-radionuclide 225Ac-J591. PATIENTS AND METHODS: Patients with progressive, metastatic androgen pathway modulation-resistant prostate cancer were enrolled in two parallel dose-escalation cohorts: (i) fractionated-dose regimen (single cycle of 45-65 KBq/kg of 225Ac-J591 on days 1 and 15; main cohort agnostic to prior receipt of 177Lu-PSMA and an additional cohort with prior receipt of 177Lu-PSMA) and (ii) multiple cycles of 225Ac-J591 (45-65 KBq/kg administered every 6 weeks for up to 4 cycles). PSMA PET was not utilized for eligibility. The primary endpoint was determination of dose-limiting toxicity (DLT) and recommended phase II dose (RP2D); the fractionated cohort was expanded. RESULTS: Forty-two patients were enrolled in the fractionated-dose regimen (23 dose-escalation, 11 dose-expansion, and 8 after 177Lu-PSMA) and 18 in multiple-dose regimen. All received ≥1 prior androgen receptor pathway inhibitor, 72% received chemotherapy, and 18% received 177Lu-PSMA. Three patients had DLTs in the fractionated regimen with RP2D of 60 KBq/kg twice. Seven had DLTs in the multiple-cycle regimen; this regimen is not recommended for further development. Among adverse events of special interest, temporary hematologic toxicity was most common [93% thrombocytopenia (32% grade >3), 65% neutropenia (13% grade ≥3), and 63% anemia (20% grade ≥3)]; dry mouth occurred in 62% (2% grade 2). Across fractionated cohorts with or without prior 177Lu-PSMA, a >50% prostate-specific antigen (PSA) decline was the best response occurring in 60% of patients; 28% had a >50% PSA decline in multiple cycles. CONCLUSIONS: Fractionated dosing of 225Ac-J591 seems promising. Further investigation is underway.
科研通智能强力驱动
Strongly Powered by AbleSci AI